Abstract
In the present investigation, a series of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2- c]pyrazole-2-carboxamide analogs were synthesized based on the structure of known antitubercular drug thiacetazone and were evaluated for antitubercular activity by two fold serial dilution technique. A computational study was carried out for prediction of pharmacokinetic properties and none of the compounds violated Lipinski “Rule of Five”. The structures of the synthesized compounds were confirmed on the basis of their spectral data and elemental analysis. All the newly synthesized compounds showed low to good activity inhibitory activities against Mycobacterium tuberculosis H37Rv (MTB) and isoniazid resistant M. tuberculosis (INHR-MTB). 3-(4-fluoromethyl)-N-(2-chlorophenyl)-6,7-dimethoxy-3a,4- dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4c) was found to be the most promising compound active against M. tuberculosis H37Rv and isoniazid resistant M. tuberculosis (INHR-MTB) with minimum inhibitory concentration 0.83 and 3.35 μM respectively.
Keywords: Pyrazolines, claisen schmidt condensation, antitubercular agents, molecular properties prediction, lipophilicity; lipinski “rule of five”
Anti-Infective Agents
Title:Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Volume: 10 Issue: 2
Author(s): Mohamed Jawed Ahsan, Jeyabalan Govinda Samy, Habibullah Khalilullah, Choudhary R. Kirit and Savita Soni
Affiliation:
Keywords: Pyrazolines, claisen schmidt condensation, antitubercular agents, molecular properties prediction, lipophilicity; lipinski “rule of five”
Abstract: In the present investigation, a series of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2- c]pyrazole-2-carboxamide analogs were synthesized based on the structure of known antitubercular drug thiacetazone and were evaluated for antitubercular activity by two fold serial dilution technique. A computational study was carried out for prediction of pharmacokinetic properties and none of the compounds violated Lipinski “Rule of Five”. The structures of the synthesized compounds were confirmed on the basis of their spectral data and elemental analysis. All the newly synthesized compounds showed low to good activity inhibitory activities against Mycobacterium tuberculosis H37Rv (MTB) and isoniazid resistant M. tuberculosis (INHR-MTB). 3-(4-fluoromethyl)-N-(2-chlorophenyl)-6,7-dimethoxy-3a,4- dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4c) was found to be the most promising compound active against M. tuberculosis H37Rv and isoniazid resistant M. tuberculosis (INHR-MTB) with minimum inhibitory concentration 0.83 and 3.35 μM respectively.
Export Options
About this article
Cite this article as:
Jawed Ahsan Mohamed, Govinda Samy Jeyabalan, Khalilullah Habibullah, R. Kirit Choudhary and Soni Savita, Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020117
DOI https://dx.doi.org/10.2174/2211362611208020117 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Perioperative Management of Hyperlipidemia Medications
Current Clinical Pharmacology Recent Advances and Future Perspectives of Triazole Analogs as Promising Antiviral Agents
Mini-Reviews in Medicinal Chemistry Suitable Multicomponent Organic Synthesis using Heteropolycompounds as Catalysts
Mini-Reviews in Organic Chemistry Alumina Sulfuric Acid: An Efficient Heterogeneous Catalyst for the Synthesis of Amidoalkyl Naphthols
Letters in Organic Chemistry Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Affinity Ligands for Industrial Protein Purification
Protein & Peptide Letters Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Vaccination Against High Blood Pressure
Current Pharmaceutical Design State of the Art and Development of a Drug-Drug Interaction Large Scale Predictor Based on 3D Pharmacophoric Similarity
Current Drug Metabolism The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia
CNS & Neurological Disorders - Drug Targets Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation
Current Drug Delivery Schizophrenia: Causes and Treatments
Current Pharmaceutical Design